2018 FDA approved the listing of new drug: DORAVIRINE
On August 30, 2018, Merck Corporation (MSD) announced that the US FDA approved two new drugs for the treatment of HIV-1 infection. Among them, DELSTRIGOTM is a once-a-day oral fixed-dose combination tablet containing doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate. , TDF, 300mg). PIFELTROTM (doravirine, 100mg) is an innovative non-nucleoside reverse transcriptase inhibitor (NNRTI) that can be used in combination with other antiviral drugs. Both DELSTRIGOTM and PIFELTROTM are used to treat adult HIV-1 infected patients who have not received antiviral therapy.
Send inquiry online For more product information and prices
(Pharmaceutical Ingredients Manufacturer & Supplier & Exporter.)
After sending the online inquiry, we will reply you as soon as possible, if not get any response on time please contact us by Tel or Email. —— Green Stone SwissEmail: [email protected]
Tel: +86 592 5365887
WhatsApp: +86 189 6515 7632
Send inquiry online: